Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
Launched by GALDERMA R&D · Sep 4, 2019
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Moderate to severe platysmal bands at maximum contraction as assessed by the Investigator using a photographic scale
- • Platysmal bands graded as Level 3 or 4 at maximum contraction as assessed by the subject using a photographic scale
- Exclusion Criteria:
- • Botulinum toxin treatment of any serotype below the lower orbital rim, in the neck or chest within 12 months prior to study treatment
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Encino, California, United States
New York, New York, United States
Encinitas, California, United States
Boynton Beach, Florida, United States
Miami, Florida, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials